260 related articles for article (PubMed ID: 25707045)
1. Anti-VEGF intravitreal bevacizumab for radiation-associated neovascular glaucoma.
Nagendran ST; Finger PT
Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):201-7. PubMed ID: 25707045
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Wakabayashi T; Oshima Y; Sakaguchi H; Ikuno Y; Miki A; Gomi F; Otori Y; Kamei M; Kusaka S; Tano Y
Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab.
Moraczewski AL; Lee RK; Palmberg PF; Rosenfeld PJ; Feuer WJ
Br J Ophthalmol; 2009 May; 93(5):589-93. PubMed ID: 19074917
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.
Mahdjoubi A; Najean M; Lemaitre S; Dureau S; Dendale R; Levy C; Rouic LL; Desjardins L; Cassoux N
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):411-420. PubMed ID: 29116399
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series.
Kotecha A; Spratt A; Ogunbowale L; dell'Omo R; Kulkarni A; Bunce C; Franks WA
Arch Ophthalmol; 2011 Feb; 129(2):145-50. PubMed ID: 21320957
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study.
Sasamoto Y; Oshima Y; Miki A; Wakabayashi T; Song D; Matsushita K; Hamasaki T; Nishida K
J Ocul Pharmacol Ther; 2012 Feb; 28(1):41-8. PubMed ID: 21992534
[TBL] [Abstract][Full Text] [Related]
7. Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma.
Mashayekhi A; Rojanaporn D; Al-Dahmash S; Shields CL; Shields JA
Eur J Ophthalmol; 2014; 24(2):228-34. PubMed ID: 23934823
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma.
Parrozzani R; Pilotto E; Dario A; Miglionico G; Midena E
Am J Ophthalmol; 2013 Jan; 155(1):127-133.e2. PubMed ID: 22995029
[TBL] [Abstract][Full Text] [Related]
9. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma.
Yeung SN; Paton KE; Waite C; Maberley DA
Can J Ophthalmol; 2010 Jun; 45(3):269-73. PubMed ID: 20379286
[TBL] [Abstract][Full Text] [Related]
11. Topical bevacizumab for neovascular glaucoma: a pilot study.
Waisbourd M; Shemesh G; Kurtz S; Rachmiel R; Moisseiev E; Zayit-Soudri S; Loewenstein A; Barequet I
Pharmacology; 2014; 93(3-4):108-12. PubMed ID: 24556733
[TBL] [Abstract][Full Text] [Related]
12. Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma.
Vásquez LM; Somani S; Altomare F; Simpson ER
Can J Ophthalmol; 2009 Feb; 44(1):106-7. PubMed ID: 19169330
[No Abstract] [Full Text] [Related]
13. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C.
Alkawas AA; Shahien EA; Hussein AM
J Glaucoma; 2010 Dec; 19(9):622-6. PubMed ID: 20179624
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial.
Yazdani S; Hendi K; Pakravan M; Mahdavi M; Yaseri M
J Glaucoma; 2009; 18(8):632-7. PubMed ID: 19826393
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.
Olmos LC; Sayed MS; Moraczewski AL; Gedde SJ; Rosenfeld PJ; Shi W; Feuer WJ; Lee RK
Eye (Lond); 2016 Mar; 30(3):463-72. PubMed ID: 26681145
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma.
Shah SU; Shields CL; Bianciotto CG; Iturralde J; Al-Dahmash SA; Say EAT; Badal J; Mashayekhi A; Shields JA
Ophthalmology; 2014 Jan; 121(1):269-275. PubMed ID: 24139123
[TBL] [Abstract][Full Text] [Related]
17. Management of neovascular glaucoma with transscleral cyclophotocoagulation with diode laser alone versus combination transscleral cyclophotocoagulation with diode laser and intravitreal bevacizumab.
Fong AW; Lee GA; O'Rourke P; Thomas R
Clin Exp Ophthalmol; 2011; 39(4):318-23. PubMed ID: 20973900
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma.
Mason JO; Albert MA; Persaud TO; Vail RS
Retina; 2007 Sep; 27(7):903-7. PubMed ID: 17891015
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up.
Arcieri ES; Paula JS; Jorge R; Barella KA; Arcieri RS; Secches DJ; Costa VP
Acta Ophthalmol; 2015 Feb; 93(1):e1-6. PubMed ID: 24989855
[TBL] [Abstract][Full Text] [Related]
20. Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab.
Wittström E; Holmberg H; Hvarfner C; Andréasson S
Eur J Ophthalmol; 2012; 22(4):563-74. PubMed ID: 22139613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]